WATERTOWN, Mass.--(BUSINESS WIRE)--
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of
sustained release drug delivery products for treating eye diseases,
today announced that its financial results for the fourth quarter and
fiscal year 2015 will be released after the market close on Wednesday,
September 9, 2015, followed the same day by a conference call and live
webcast scheduled for 4:30 p.m. ET.
The conference call may be accessed by dialing (877) 312-7507 from the
U.S. and Canada, or (631) 813-4828 from international locations. The
conference ID is 27613566. A live webcast will be available on the
Investor Relations section of the corporate website at http://www.psivida.com.
A replay of the call will be available beginning September 9, 2015, at
approximately 7:30 p.m. ET and ending on September 16, 2015, at 11:59
p.m. ET. The replay may be accessed by dialing (855) 859-2056 within the
U.S. and Canada or (404) 537-3406 from international locations,
Conference ID Number: 27613566. A replay of the webcast will also be
available on the corporate website during that time.
About pSivida Corp.
pSivida Corp. (www.psivida.com),
headquartered in Watertown, MA, is a leader in the development of
sustained release, drug delivery products for treating eye diseases.
pSivida has developed three of only four FDA-approved treatments for
back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for
diabetic macular edema, is licensed to Alimera Sciences and sold in the
U.S. and three EU countries. Retisert®, an implant for posterior
uveitis, is licensed to and sold by Bausch & Lomb. pSivida's lead
product candidate, Medidur™, a micro-insert for posterior uveitis, is in
Phase III clinical trials with an NDA anticipated as early as the first
half of 2017. pSivida's pre-clinical development program is focused on
using its core platform technologies, Durasert™ and/or Tethadur™, to
deliver drugs and biologics to treat wet and dry age-related macular
degeneration (AMD), glaucoma, osteoarthritis and other diseases.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties and
potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or believe may
occur in the future are forward-looking statements. Some of the factors
that could cause actual results to differ materially from the
anticipated results or other expectations expressed, anticipated or
implied in our forward-looking statements include uncertainties with
respect to: actual final IOP safety results for Medidur Phase III
trials; ability to achieve profitable operations and access to capital;
fluctuations in operating results; further impairment of intangible
assets; decline in Retisert royalties; successful commercialization of,
and receipt of revenues from, ILUVIEN for DME; effect of pricing and
reimbursement decisions on sales of ILUVIEN for DME; consequences of
flucinolone acetonide side effects; number and cost of clinical trials
and data necessary to support an NDA for, approval by Indian regulators
of the trial design for, timing of filing the NDA for, and regulatory
approval and successful commercialization of, Medidur; delays in
completion of clinical trials; increases in cost of clinical trials;
changes in, or misunderstandings with respect to, FDA guidance on
required clinical trials; development of the Latanoprost Product and any
exercise by Pfizer of its option; ability of Tethadur to successfully
deliver large biologic molecules and to develop products using it;
ability to successfully develop product candidates, complete clinical
trials and receive regulatory approvals; ability to market and sell
products; success of current and future license agreements; termination
of license agreements; effects of competition and other developments
affecting sales of products; market acceptance of products; effects of
guidelines, recommendations and studies; protection of intellectual
property and avoiding intellectual property infringement; retention of
key personnel; product liability; industry consolidation; compliance
with environmental laws; manufacturing risks; risks and costs of
international business operations; legislative or regulatory changes;
volatility of stock price; possible dilution; absence of dividends; and
other factors described in our filings with the SEC. You should read and
interpret any forward-looking statements together with these risks.
Should known or unknown risks materialize, or should underlying
assumptions prove inaccurate, actual results could differ materially
from past results and those anticipated, estimated or projected in the
forward-looking statements. You should bear this in mind as you consider
any forward-looking statements. Our forward-looking statements speak
only as of the dates on which they are made. We do not undertake any
obligation to publicly update or revise our forward-looking statements
even if experience or future changes makes it clear that any projected
results expressed or implied in such statements will not be realized.
Follow pSivida on social media:
Twitter: https://twitter.com/pSividaCorp
Facebook: https://www.facebook.com/pages/PSivida-Corp/544893792199562
LinkedIn: http://www.linkedin.com/company/psivida
Google+: https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts
The President's Blog: http://www.thechairmansblog.com/paul-ashton
For more information on pSivida, visit www.psivida.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150902005346/en/
Martin E. Janis & Company, Inc.
Beverly Jedynak
President
T:
312-943-1123
M: 773-350-5793
bjedynak@janispr.com
Source: pSivida Corp.
News Provided by Acquire Media
